David Alland mainly investigates Mycobacterium tuberculosis, Genetics, Tuberculosis, Drug resistance and GeneXpert MTB/RIF. David Alland works in the field of Mycobacterium tuberculosis, focusing on rpoB in particular. His Tuberculosis research incorporates elements of Internal medicine and Restriction fragment length polymorphism.
His Drug resistance course of study focuses on Rifampicin and Virology. His GeneXpert MTB/RIF research is multidisciplinary, incorporating elements of Multiple drug resistance, Tuberculosis diagnosis, Antibacterial agent and Clinical trial. David Alland works mostly in the field of Microbiology, limiting it down to concerns involving Nucleic acid amplification technique and, occasionally, Genotype.
David Alland mostly deals with Mycobacterium tuberculosis, Tuberculosis, Drug resistance, Microbiology and Genetics. His Mycobacterium tuberculosis research is multidisciplinary, incorporating perspectives in Antibacterial agent, Rifampicin, Virology, Gene and Isoniazid. His biological study spans a wide range of topics, including Multiple drug resistance and Ethambutol.
The study incorporates disciplines such as Internal medicine, In vitro and Molecular epidemiology in addition to Tuberculosis. His study in Drug resistance is interdisciplinary in nature, drawing from both Dihydrofolate reductase, Demographic data, Gerontology and Genotype. His Microbiology research integrates issues from Mycobacterium bovis, Amplicon, Sepsis and Enzyme.
The scientist’s investigation covers issues in Mycobacterium tuberculosis, Molecular biology, Sanger sequencing, Gene and Drug resistance. Mycobacterium tuberculosis is a subfield of Tuberculosis that David Alland studies. In his research, Bacteremia and Sputum culture is intimately related to Internal medicine, which falls under the overarching field of Tuberculosis.
His studies deal with areas such as Chromatin and Peptide sequence as well as Molecular biology. His Gene study integrates concerns from other disciplines, such as Proteases, Biophysics, DNA and Trypsin. While the research belongs to areas of Drug resistance, David Alland spends his time largely on the problem of Kanamycin, intersecting his research to questions surrounding Sequence analysis.
Mycobacterium tuberculosis, Drug resistance, Tuberculosis, Prospective cohort study and Internal medicine are his primary areas of study. The Mycolic acid research he does as part of his general Mycobacterium tuberculosis study is frequently linked to other disciplines of science, such as Transmembrane protein, therefore creating a link between diverse domains of science. The concepts of his Drug resistance study are interwoven with issues in Medical microbiology, Sputum, Medical history and History of tuberculosis.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Rapid molecular detection of tuberculosis and rifampin resistance.
Catharina C. Boehme;Pamela Nabeta;Doris Hillemann;Mark P. Nicol.
The New England Journal of Medicine (2010)
Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study
Catharina C. Boehme;Mark P. Nicol;Mark P. Nicol;Pamela Nabeta;Joy S. Michael.
The Lancet (2011)
A detailed analysis of 16S ribosomal RNA gene segments for the diagnosis of pathogenic bacteria.
Soumitesh Chakravorty;Danica Helb;Michele Burday;Nancy Connell.
Journal of Microbiological Methods (2007)
Transmission of Tuberculosis in New York City. An Analysis by DNA Fingerprinting and Conventional Epidemiologic Methods
David Alland;Gary E. Kalkut;Andrew R. Moss;Ruth A. McAdam.
The New England Journal of Medicine (1994)
Rapid Detection of Mycobacterium tuberculosis and Rifampin Resistance by Use of On-Demand, Near-Patient Technology
Danica Helb;Martin Jones;Elizabeth Story;Catharina Boehme.
Journal of Clinical Microbiology (2010)
Whole-Genome Comparison of Mycobacterium tuberculosis Clinical and Laboratory Strains
R. D. Fleischmann;D. Alland;Jonathan A Eisen;L. Carpenter.
Journal of Bacteriology (2002)
Evaluation of the Analytical Performance of the Xpert MTB/RIF Assay
Robert Blakemore;Elizabeth Story;Danica Helb;JoAnn Kop.
Journal of Clinical Microbiology (2010)
Molecular beacon sequence analysis for detecting drug resistance in Mycobacterium tuberculosis
Amy S. Piatek;Sanjay Tyagi;Arno C. Pol;Amalio Telenti.
Nature Biotechnology (1998)
A Multi-institutional Outbreak of Highly Drug-Resistant Tuberculosis: Epidemiology and Clinical Outcomes
Thomas R. Frieden;Lisa Fine Sherman;Khin Lay Maw;Paula I. Fujiwara.
Variation in virulence among clades of Escherichia coli O157:H7 associated with disease outbreaks
Shannon D. Manning;Alifiya S. Motiwala;A. Cody Springman;Weihong Qi.
Proceedings of the National Academy of Sciences of the United States of America (2008)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: